Novaliq

Novaliq is a private, clinical-stage biotech pioneering a novel, water-free drug delivery platform (EyeSol®) for ophthalmology. Its technology is designed to enhance drug bioavailability, retention time, and tolerability on the ocular surface. The company has achieved its first commercial approvals in the US for dry eye disease (NOV03, CyclASol) and is advancing a pipeline targeting glaucoma, diabetic retinopathy, dermatology, and uveitis. With a seasoned management team and strategic partnerships, Novaliq is positioned to challenge the standard of care in topical ocular therapeutics.

EyeSol®, the world's first water-free technology platform for ophthalmic products. It uses semifluorinated alkanes to enhance drug bioavailability, increase ocular surface retention time, enable micro-dosing, and eliminate the need for preservatives.

Novaliq competes in ophthalmology with large players like AbbVie (Allergan), Novartis, and Bausch + Lomb, as well as specialist biotechs like Aldeyra and Kala Pharmaceuticals. Its primary competitive edge is its proprietary, water-free platform, which aims to demonstrate superior efficacy, tolerability, and dosing convenience compared to traditional aqueous formulations and other novel delivery systems.